Sodium-glucose cotransporter-2 inhibitors and their potential role in dementia onset and cognitive function in patients with diabetes mellitus: a systematic review and meta-analysis.
SGLT2抑制劑在糖尿病患者中對失智症發病和認知功能的潛在作用:系統性回顧和荟萃分析。
Front Neuroendocrinol 2024-02-24
SGLT2 inhibitors: a novel therapy for cognitive impairment via multifaceted effects on the nervous system.
SGLT2 抑制劑:通過對神經系統的多方面影響治療認知障礙的新療法。
Transl Neurodegener 2024-08-09
Neuroprotective Effects of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors (Gliflozins) on Diabetes-Induced Neurodegeneration and Neurotoxicity: A Graphical Review.
鈉-葡萄糖共轉運蛋白-2 (SGLT2) 抑制劑 (Gliflozins) 對糖尿病引起的神經退行性變和神經毒性的神經保護作用:圖形回顧。
Int J Prev Med 2024-09-06
Exploring the Therapeutic Potential of DPP4 Inhibitors in Alzheimer's Disease: Molecular Insight and Clinical Outcome.
探索 DPP4 抑制劑在阿茲海默症中的治療潛力:分子洞察與臨床結果。
Cureus 2024-11-29
The Promising Potency of Sodium-Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients.
鈉-葡萄糖共轉運蛋白 2 抑制劑在預防及治療 2 型糖尿病患者認知障礙中的潛在效能。
Biomedicines 2025-01-08
Unveiling the mTOR pathway modulation by SGLT2 inhibitors: a novel approach to Alzheimer's disease in type 2 diabetes.
揭示 SGLT2 抑制劑對 mTOR 通路的調節:一種針對 2 型糖尿病中阿茲海默症的新方法。
Metab Brain Dis 2025-02-26
Neuroprotective effects of SGLT2 inhibitors empagliflozin and dapagliflozin on Aβ<sub>1-42</sub>-induced neurotoxicity and neuroinflammation in cellular models of Alzheimer's disease.
SGLT2 抑制劑 empagliflozin 和 dapagliflozin 對 Aβ<sub>1-42</sub> 引起的神經毒性和神經炎症在阿茲海默症細胞模型中的神經保護作用。
J Alzheimers Dis 2025-03-20
本研究探討鈉-葡萄糖共轉運蛋白-2 抑制劑(SGLT2i),如 empagliflozin 和 dapagliflozin,對阿茲海默症中 tau 磷酸化、氧化壓力及神經炎症的保護效果。結果顯示,這些抑制劑能逆轉 Aβ<sub>1-42</sub> 對細胞活性和凋亡的影響,並減少活性氧生成及 NLRP3-炎症小體表達,改善 tau 病理。研究還發現,這些藥物在大腦中的分佈可透過 Elacridar 改善,顯示出其潛在的神經保護效果。
PubMedDOI
Reducing Alzheimer's Disease Risk with SGLT2 Inhibitors: From Glycemic Control to Neuroprotection.
使用 SGLT2 抑制劑降低阿茲海默症風險:從血糖控制到神經保護。
Ageing Res Rev 2025-04-09